FDA warned Applied Biological Laboratories that its Biovanta throat spray and lozenges are unapproved, misbranded drugs promoted for COVID-19.
What happened
FDA reviewed the company’s websites biovanta.com and appliedbioinc.com in February and March 2022, and also reviewed social media pages, and found Biovanta Dual Action Throat Spray and Biovanta Triple Action Lozenges offered for sale with claims to mitigate, prevent, treat, diagnose, or cure COVID-19. FDA says these are unapproved new drugs and misbranded drugs. FTC also reviewed the websites in March 2022 and demanded that the company stop making unsubstantiated COVID-19 claims.
What FDA found
Biovanta Dual Action Throat Spray and Biovanta Triple Action Lozenges are unapproved new drugs because they are intended for COVID-19 and have not been approved by FDA.
section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)The products are misbranded drugs under the FD&C Act.
section 502 of the FD&C Act, 21 U.S.C. § 352The company introduced or delivered for introduction these products into interstate commerce, which the FD&C Act prohibits for such products.
sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)The company advertised that Biovanta products can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence.
FTC Act, 15 U.S.C. § 41 et seq.
What FDA wants
FDA tells the company to immediately stop selling unapproved products for COVID-19, review websites, labels, and promotional materials, and email FDA within 48 hours describing corrective steps. FTC separately requires certification within 48 hours that unsubstantiated claims have stopped.
Who should pay attention
- retailers and online marketplaces selling Biovanta products
- companies making COVID-19-related claims for OTC remedies
- brands using social media influencers or testimonials for health claims
This is a summary. Read the original letter on fda.gov.